BEAM · Beam Therapeutics Inc.
$23.99
-1.56% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-5.1
Dividend yield
—
Beta
2.23
Avg volume
2M
Employees
1K
Daily Change %
-1.56%
5 Days Change
-15.12%
10 Days Change
-14.46%
30 Days Change
-6.24%
60 Days Change
-22.97%
Month to Day Change
-13.25%
Year to Day Change
-9.18%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BEAM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Bank of America
Buy$47.00
+92.9% vs priceCitigroup
Buy$68.00
+179.0% vs priceRBC Capital
Sector Perform$26.00
+6.7% vs priceUBS
Neutral$28.00
+14.9% vs priceJP Morgan
Overweight$46.00
+88.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Wedbush | Reiterates | Outperform | $65.00 |
| 2026-08-25 | HC Wainwright & Co. | Reiterates | Buy | $80.00 |
| 2026-07-08 | Bank of America | Reiterates | Buy | $47.00 |
| 2026-07-07 | HC Wainwright & Co. | Reiterates | Buy | $80.00 |
| 2026-05-13 | Bernstein | Maintains | Outperform | $40.00 → $39.00 |
| 2026-03-26 | Citigroup | Maintains | Buy | $64.00 → $68.00 |
| 2026-02-25 | RBC Capital | Maintains | Sector Perform | $22.00 → $26.00 |
| 2026-02-25 | Wedbush | Maintains | Outperform | $57.00 → $65.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 16.1% below the 50-day MA ($28.61).
- Price vs 200-day MA: Trading 16.1% below the 200-day MA ($28.60).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.59) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($20.60) and high ($37.92).
BEAM Price Chart
Loading chart for BEAM…
Fundamentals
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.